메뉴 건너뛰기




Volumn 7, Issue , 2015, Pages 189-203

New perspectives on targeted therapy in ovarian cancer

Author keywords

Antiangiogenic therapy; Cancer related inflammation; High grade serous; Low grade ovarian cancer; PARP inhibition

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FARLETUZUMAB; GEFITINIB; GEMCITABINE; IRINOTECAN; NINTEDANIB; NIRAPARIB; OLAPARIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; TREBANANIB; UNINDEXED DRUG; VASCULOTROPIN A;

EID: 84922354674     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S52379     Document Type: Article
Times cited : (86)

References (122)
  • 1
    • 33644931626 scopus 로고    scopus 로고
    • Worldwide burden of gynaecological cancer: The size of the problem
    • Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207-225.
    • (2006) Best Pract Res Clin Obstet Gynaecol , vol.20 , Issue.2 , pp. 207-225
    • Sankaranarayanan, R.1    Ferlay, J.2
  • 2
    • 0026491126 scopus 로고
    • Cancer mortality in African and Caribbean migrants to England and Wales
    • Grulich AE, Swerdlow AJ, Head J, Marmot MG. Cancer mortality in African and Caribbean migrants to England and Wales. Br J Cancer. 1992;66(5):905-911.
    • (1992) Br J Cancer , vol.66 , Issue.5 , pp. 905-911
    • Grulich, A.E.1    Swerdlow, A.J.2    Head, J.3    Marmot, M.G.4
  • 3
    • 0027050477 scopus 로고
    • Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer
    • Whittemore AS, Harris R, Itnyre J; Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Am J Epidemiol. 1992;136(10):1212-1220.
    • (1992) Am J Epidemiol , vol.136 , Issue.10 , pp. 1212-1220
    • Whittemore, A.S.1    Harris, R.2    Itnyre, J.3
  • 4
    • 0031799507 scopus 로고    scopus 로고
    • Epidemiology and risk assessment for ovarian cancer
    • Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol. 1998;25(3):255-264.
    • (1998) Semin Oncol , vol.25 , Issue.3 , pp. 255-264
    • Daly, M.1    Obrams, G.I.2
  • 5
    • 0027018453 scopus 로고
    • Cancer Incidence in Five Continents. Comparability and quality of data
    • Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ. 1992;(120):45-173.
    • (1992) IARC Sci Publ , Issue.120 , pp. 45-173
    • Parkin, D.M.1    Muir, C.S.2
  • 6
    • 67349224121 scopus 로고    scopus 로고
    • Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
    • Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26-31.
    • (2009) Gynecol Oncol , vol.114 , Issue.1 , pp. 26-31
    • Chi, D.S.1    Eisenhauer, E.L.2    Zivanovic, O.3
  • 7
    • 0033061436 scopus 로고    scopus 로고
    • High-dose chemotherapy in ovarian carcinoma
    • Herrin VE, Thigpen JT. High-dose chemotherapy in ovarian carcinoma. Semin Oncol. 1999;26(1):99-105.
    • (1999) Semin Oncol , vol.26 , Issue.1 , pp. 99-105
    • Herrin, V.E.1    Thigpen, J.T.2
  • 8
    • 65449185885 scopus 로고    scopus 로고
    • Management of early ovarian cancer
    • Sonoda Y. Management of early ovarian cancer. Oncology (Williston Park). 2004;18(3):343-356.
    • (2004) Oncology (Williston Park) , vol.18 , Issue.3 , pp. 343-356
    • Sonoda, Y.1
  • 9
    • 0030054309 scopus 로고    scopus 로고
    • Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    • McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.
    • (1996) N Engl J Med , vol.334 , Issue.1 , pp. 1-6
    • McGuire, W.P.1    Hoskins, W.J.2    Brady, M.F.3
  • 10
    • 0033850178 scopus 로고    scopus 로고
    • Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
    • Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084-3092.
    • (2000) J Clin Oncol , vol.18 , Issue.17 , pp. 3084-3092
    • Neijt, J.P.1    Engelholm, S.A.2    Tuxen, M.K.3
  • 11
    • 63049115790 scopus 로고    scopus 로고
    • Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup
    • Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419-1425.
    • (2009) J Clin Oncol , vol.27 , Issue.9 , pp. 1419-1425
    • Bookman, M.A.1    Brady, M.F.2    McGuire, W.P.3
  • 12
    • 84882998935 scopus 로고    scopus 로고
    • Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial
    • Katsumata N, Yasuda M, Isonishi S, et al. Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020-1026.
    • (2013) Lancet Oncol , vol.14 , Issue.10 , pp. 1020-1026
    • Katsumata, N.1    Yasuda, M.2    Isonishi, S.3
  • 13
    • 0020453283 scopus 로고
    • Intraperitoneal cisplatin with systemic thiosulfate protection
    • Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97(6):845-851.
    • (1982) Ann Intern Med , vol.97 , Issue.6 , pp. 845-851
    • Howell, S.B.1    Pfeifle, C.L.2    Wung, W.E.3
  • 14
    • 0027101782 scopus 로고
    • Phase I trial of intraperitoneal taxol: A Gynecoloic Oncology Group study
    • Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10(9):1485-1491.
    • (1992) J Clin Oncol , vol.10 , Issue.9 , pp. 1485-1491
    • Markman, M.1    Rowinsky, E.2    Hakes, T.3
  • 15
    • 30044438368 scopus 로고    scopus 로고
    • Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    • Armstrong DK, Bundy B, Wenzel L, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
    • (2006) N Engl J Med , vol.354 , Issue.1 , pp. 34-43
    • Armstrong, D.K.1    Bundy, B.2    Wenzel, L.3
  • 16
    • 84894679203 scopus 로고    scopus 로고
    • Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study
    • Tewari D, Sill M, Monk B, et al. Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2013;1:e2.
    • (2013) Gynecol Oncol , vol.1
    • Tewari, D.1    Sill, M.2    Monk, B.3
  • 17
    • 84966309393 scopus 로고    scopus 로고
    • Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
    • Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(11):CD005340.
    • (2011) Cochrane Database Syst Rev , Issue.11
    • Jaaback, K.1    Johnson, N.2    Lawrie, T.A.3
  • 18
    • 80053168788 scopus 로고    scopus 로고
    • Rethinking ovarian cancer: Recommendations for improving outcomes
    • Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719-725.
    • (2011) Nat Rev Cancer , vol.11 , Issue.10 , pp. 719-725
    • Vaughan, S.1    Coward, J.I.2    Bast, R.C.3
  • 19
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
    • Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
    • (2007) J Clin Oncol , vol.25 , Issue.33 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 20
    • 36849056497 scopus 로고    scopus 로고
    • Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    • Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-5186.
    • (2007) J Clin Oncol , vol.25 , Issue.33 , pp. 5180-5186
    • Cannistra, S.A.1    Matulonis, U.A.2    Penson, R.T.3
  • 21
    • 84855425106 scopus 로고    scopus 로고
    • Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer
    • Burger RA, Brady MF, Bookman MA, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.
    • (2011) N Engl J Med , vol.365 , Issue.26 , pp. 2473-2483
    • Burger, R.A.1    Brady, M.F.2    Bookman, M.A.3
  • 22
    • 84855466019 scopus 로고    scopus 로고
    • ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer
    • Perren TJ, Swart AM, Pfisterer J, et al; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-2496.
    • (2011) N Engl J Med , vol.365 , Issue.26 , pp. 2484-2496
    • Perren, T.J.1    Swart, A.M.2    Pfisterer, J.3
  • 23
    • 84885334240 scopus 로고    scopus 로고
    • ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Ledermann JA, Raja FA, Fotopoulou C, et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi24-vi32.
    • (2013) Ann Oncol , vol.24 , pp. vi24-vi32
    • Ledermann, J.A.1    Raja, F.A.2    Fotopoulou, C.3
  • 24
    • 84908319663 scopus 로고    scopus 로고
    • Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab
    • May 30-June 3, Chicago, Illinois. Abstract
    • Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 5502.
    • (2014) Presented At: 2014 ASCO Annual Meeting
    • Gourley, C.1    McCavigan, A.2    Perren, T.3
  • 25
    • 84861736119 scopus 로고    scopus 로고
    • OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
    • (2012) J Clin Oncol , vol.30 , Issue.17 , pp. 2039-2045
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3
  • 26
    • 84899837376 scopus 로고    scopus 로고
    • Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
    • Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308.
    • (2014) J Clin Oncol , vol.32 , Issue.13 , pp. 1302-1308
    • Pujade-Lauraine, E.1    Hilpert, F.2    Weber, B.3
  • 27
    • 84873619713 scopus 로고    scopus 로고
    • Targeted anti-vascular therapies for ovarian cancer: Current evidence
    • Hall M, Gourley C, McNeish I, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013;108(2):250-258.
    • (2013) Br J Cancer , vol.108 , Issue.2 , pp. 250-258
    • Hall, M.1    Gourley, C.2    McNeish, I.3
  • 28
    • 84995892664 scopus 로고    scopus 로고
    • The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic Opportunities
    • Accessed December 1, 2014
    • Leary A. The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic Opportunities. Rijeka, Croatia: Intech; 2013. Available from: http://dx.doi.org/10.5772/54170. Accessed December 1, 2014.
    • (2013) Rijeka, Croatia: Intech
    • Leary, A.1
  • 29
    • 84901635787 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: A systematic review
    • Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res. 2014;7:57.
    • (2014) J Ovarian Res , vol.7
    • Aravantinos, G.1    Pectasides, D.2
  • 30
    • 81255185158 scopus 로고    scopus 로고
    • Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
    • Coleman RL, Duska LR, Ramirez PT, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011;12(12):1109-1117.
    • (2011) Lancet Oncol , vol.12 , Issue.12 , pp. 1109-1117
    • Coleman, R.L.1    Duska, L.R.2    Ramirez, P.T.3
  • 31
    • 84856509199 scopus 로고    scopus 로고
    • Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study
    • Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154-162.
    • (2012) Lancet Oncol , vol.13 , Issue.2 , pp. 154-162
    • Gotlieb, W.H.1    Amant, F.2    Advani, S.3
  • 32
    • 80053561888 scopus 로고    scopus 로고
    • Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
    • Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29(28):3798-3804.
    • (2011) J Clin Oncol , vol.29 , Issue.28 , pp. 3798-3804
    • Ledermann, J.A.1    Hackshaw, A.2    Kaye, S.3
  • 33
    • 84894046261 scopus 로고    scopus 로고
    • AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy/−nintedanib for advanced ovarian cancer [abstract]
    • LBA1
    • Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy/−nintedanib for advanced ovarian cancer [abstract]. Int J Gynecol Cancer. 2013;23(suppl 1):LBA1.
    • (2013) Int J Gynecol Cancer , vol.23
    • Du Bois, A.1    Kristensen, G.2    Ray-Coquard, I.3
  • 34
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
    • (2000) Nature , vol.407 , Issue.6801 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 35
    • 84894070693 scopus 로고    scopus 로고
    • A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer [abstract]: TRINOVA-1
    • LBA:41
    • Monk BJ, Poveda A, Vergote I, et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer [abstract]: TRINOVA-1. Eur J Cancer. 2013;49(3):LBA:41.
    • (2013) Eur J Cancer , vol.49 , Issue.3
    • Monk, B.J.1    Poveda, A.2    Vergote, I.3
  • 36
    • 84897899201 scopus 로고    scopus 로고
    • Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer
    • Davidson BA, Secord AA. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. Int J Womens Health. 2014 13;6:289-300.
    • (2014) Int J Womens Health , vol.13 , Issue.6 , pp. 289-300
    • Davidson, B.A.1    Secord, A.A.2
  • 37
    • 77956649079 scopus 로고    scopus 로고
    • A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
    • Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32-37.
    • (2010) Gynecol Oncol , vol.119 , Issue.1 , pp. 32-37
    • Friedlander, M.1    Hancock, K.C.2    Rischin, D.3
  • 38
    • 84908334026 scopus 로고    scopus 로고
    • Incorporation of pazopanib in maintenance therapy of ovarian cancer
    • du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374-3382.
    • (2014) J Clin Oncol , vol.32 , Issue.30 , pp. 3374-3382
    • Du Bois, A.1    Floquet, A.2    Kim, J.W.3
  • 39
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
    • Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337.
    • (2003) Clin Cancer Res , vol.9 , Issue.1 , pp. 327-337
    • Mendel, D.B.1    Laird, A.D.2    Xin, X.3
  • 40
    • 79251585977 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study
    • Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2011;22(2):335-340.
    • (2011) Ann Oncol , vol.22 , Issue.2 , pp. 335-340
    • Biagi, J.J.1    Oza, A.M.2    Chalchal, H.I.3
  • 41
    • 84865556743 scopus 로고    scopus 로고
    • A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
    • Baumann KH, du Bois A, Meier W, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. 2012;23(9):2265-2271.
    • (2012) Ann Oncol , vol.23 , Issue.9 , pp. 2265-2271
    • Baumann, K.H.1    Du Bois, A.2    Meier, W.3
  • 42
    • 84872869916 scopus 로고    scopus 로고
    • A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
    • Campos SM, Penson RT, Matulonis U, et al. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013;128(2):215-220.
    • (2013) Gynecol Oncol , vol.128 , Issue.2 , pp. 215-220
    • Campos, S.M.1    Penson, R.T.2    Matulonis, U.3
  • 43
    • 79951988792 scopus 로고    scopus 로고
    • Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial
    • Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011;29(1):69-75.
    • (2011) J Clin Oncol , vol.29 , Issue.1 , pp. 69-75
    • Matei, D.1    Sill, M.W.2    Lankes, H.A.3
  • 44
    • 84879112772 scopus 로고    scopus 로고
    • A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma
    • Herzog TJ, Scambia G, Kim BG, et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol. 2013;130(1):25-30.
    • (2013) Gynecol Oncol , vol.130 , Issue.1 , pp. 25-30
    • Herzog, T.J.1    Scambia, G.2    Kim, B.G.3
  • 45
    • 84922342511 scopus 로고    scopus 로고
    • Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute
    • May 31-June 4,, Chicago, Illinois. Abstract 5513
    • Thompson DS, Dudley BS, Bismayer JA, et al. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute. Presented at: 2013 ASCO Annual Meeting; May 31-June 4, 2014; Chicago, Illinois. Abstract 5513.
    • (2014) Presented At: 2013 ASCO Annual Meeting
    • Thompson, D.S.1    Dudley, B.S.2    Bismayer, J.A.3
  • 46
    • 73949123481 scopus 로고    scopus 로고
    • Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    • Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601-5606.
    • (2009) J Clin Oncol , vol.27 , Issue.33 , pp. 5601-5606
    • Matulonis, U.A.1    Berlin, S.2    Ivy, P.3
  • 47
    • 84894050019 scopus 로고    scopus 로고
    • Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
    • Abstract 10
    • Ledermann JA, Perren TJ, Raja FA, et al. Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. European J of Cancer. 2013;49(Suppl 3):Abstract 10.
    • (2013) European J of Cancer , vol.49
    • Ledermann, J.A.1    Perren, T.J.2    Raja, F.A.3
  • 48
    • 66149083645 scopus 로고    scopus 로고
    • Ovarian cancer
    • Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009;4(1):287-313.
    • (2009) Annu Rev Pathol , vol.4 , Issue.1 , pp. 287-313
    • Cho, K.R.1    Shih, I.2
  • 49
    • 67349236109 scopus 로고    scopus 로고
    • Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
    • Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.Gynecol Oncol. 2009;114(1):48-52.
    • (2009) Gynecol Oncol , vol.114 , Issue.1 , pp. 48-52
    • Gershenson, D.M.1    Sun, C.C.2    Bodurka, D.3
  • 50
    • 39249083491 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
    • Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108(3):510-514.
    • (2008) Gynecol Oncol , vol.108 , Issue.3 , pp. 510-514
    • Schmeler, K.M.1    Sun, C.C.2    Bodurka, D.C.3
  • 51
    • 84862804745 scopus 로고    scopus 로고
    • Ovarian serous carcinoma: Recent concepts on its origin and carcinogenesis
    • Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5:8.
    • (2012) J Hematol Oncol , vol.5
    • Li, J.1    Fadare, O.2    Xiang, L.3    Kong, B.4    Zheng, W.5
  • 52
    • 79959838081 scopus 로고    scopus 로고
    • Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma
    • Bell D, Berchuck A, Birrer M, et al. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
    • (2011) Nature , vol.474 , Issue.7353 , pp. 609-615
    • Bell, D.1    Berchuck, A.2    Birrer, M.3
  • 53
    • 84873079682 scopus 로고    scopus 로고
    • Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study
    • Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134-140.
    • (2013) Lancet Oncol , vol.14 , Issue.2 , pp. 134-140
    • Farley, J.1    Brady, W.E.2    Vathipadiekal, V.3
  • 54
    • 84946222402 scopus 로고    scopus 로고
    • The life and times of low-grade serous carcinoma of the ovary
    • May 31-June 4, 2014; Chicago, Illinois
    • Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. Presented at: 2013 ASCO Annual Meeting; May 31-June 4, 2014; Chicago, Illinois.
    • Presented At: 2013 ASCO Annual Meeting
    • Gershenson, D.M.1
  • 55
    • 84857432805 scopus 로고    scopus 로고
    • Molecular approaches to personalizing management of ovarian cancer
    • Bast RC Jr. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22 (Suppl 8):viii5-viii15.
    • (2011) Ann Oncol , vol.22 , pp. viiiviii5-viii15
    • Bast, R.C.1
  • 56
    • 33746646758 scopus 로고    scopus 로고
    • Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
    • Kojima K, Konopleva M, McQueen T, O’Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006;108(3):993-1000.
    • (2006) Blood , vol.108 , Issue.3 , pp. 993-1000
    • Kojima, K.1    Konopleva, M.2    McQueen, T.3    O’Brien, S.4    Plunkett, W.5    Reeff, M.6
  • 58
    • 79959328816 scopus 로고    scopus 로고
    • Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm
    • Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42(7):918-931.
    • (2011) Hum Pathol , vol.42 , Issue.7 , pp. 918-931
    • Kurman, R.J.1    Shih, I.E.2
  • 59
    • 79954570471 scopus 로고    scopus 로고
    • IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
    • Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17(8):2538-2548.
    • (2011) Clin Cancer Res , vol.17 , Issue.8 , pp. 2538-2548
    • Anglesio, M.S.1    George, J.2    Kulbe, H.3
  • 60
    • 79959923767 scopus 로고    scopus 로고
    • Identification of novel therapeutic targets in microdissected clear cell ovarian cancers
    • Stany MP, Vathipadiekal V, Ozbun L, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS ONE. 2011;6(7):e21121.
    • (2011) Plos ONE , vol.6 , Issue.7
    • Stany, M.P.1    Vathipadiekal, V.2    Ozbun, L.3
  • 61
    • 78649486193 scopus 로고    scopus 로고
    • GINECO. Mucinous advanced epithelial ovarian carcinoma: Clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience
    • Alexandre J, Ray-Coquard I, Selle F, et al. GINECO. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010;21(12):2377-2381.
    • (2010) Ann Oncol , vol.21 , Issue.12 , pp. 2377-2381
    • Alexandre, J.1    Ray-Coquard, I.2    Selle, F.3
  • 62
    • 84872862768 scopus 로고    scopus 로고
    • Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas
    • Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111-120.
    • (2013) J Pathol , vol.229 , Issue.1 , pp. 111-120
    • Anglesio, M.S.1    Kommoss, S.2    Tolcher, M.C.3
  • 63
    • 84903146674 scopus 로고    scopus 로고
    • Advanced epithelial ovarian cancer: From standard chemotherapy to promising molecular pathway targets-where are we now?
    • Syrios J, Banerjee S, Kaye SB. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets-where are we now? Anticancer Res. 2014;34(5):2069-2077.
    • (2014) Anticancer Res , vol.34 , Issue.5 , pp. 2069-2077
    • Syrios, J.1    Banerjee, S.2    Kaye, S.B.3
  • 64
    • 0037440042 scopus 로고    scopus 로고
    • Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    • Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283-290.
    • (2003) J Clin Oncol , vol.21 , Issue.2 , pp. 283-290
    • Bookman, M.A.1    Darcy, K.M.2    Clarke-Pearson, D.3    Boothby, R.A.4    Horowitz, I.R.5
  • 65
    • 74049094790 scopus 로고    scopus 로고
    • HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
    • McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9(1):433.
    • (2009) BMC Cancer , vol.9 , Issue.1
    • McAlpine, J.N.1    Wiegand, K.C.2    Vang, R.3
  • 66
    • 80052588957 scopus 로고    scopus 로고
    • Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
    • Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;123(1):19-26.
    • (2011) Gynecol Oncol , vol.123 , Issue.1 , pp. 19-26
    • Behbakht, K.1    Sill, M.W.2    Darcy, K.M.3
  • 67
    • 17244373777 scopus 로고    scopus 로고
    • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    • Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.
    • (2005) Nature , vol.434 , Issue.7035 , pp. 917-921
    • Farmer, H.1    McCabe, N.2    Lord, C.J.3
  • 68
    • 17244375049 scopus 로고    scopus 로고
    • Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    • Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917.
    • (2005) Nature , vol.434 , Issue.7035 , pp. 913-917
    • Bryant, H.E.1    Schultz, N.2    Thomas, H.D.3
  • 69
    • 0036733355 scopus 로고    scopus 로고
    • The therapeutic potential of poly(ADP-ribose) polymerase inhibitors
    • Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375-429.
    • (2002) Pharmacol Rev , vol.54 , Issue.3 , pp. 375-429
    • Virág, L.1    Szabó, C.2
  • 70
    • 49249119415 scopus 로고    scopus 로고
    • A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    • Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785-3790.
    • (2008) J Clin Oncol , vol.26 , Issue.22 , pp. 3785-3790
    • Ashworth, A.1
  • 71
    • 0038744296 scopus 로고    scopus 로고
    • Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies
    • Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
    • (2003) Am J Hum Genet , vol.72 , Issue.5 , pp. 1117-1130
    • Antoniou, A.1    Pharoah, P.D.2    Narod, S.3
  • 72
    • 81055126264 scopus 로고    scopus 로고
    • Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
    • Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-18037.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , Issue.44 , pp. 18032-18037
    • Walsh, T.1    Casadei, S.2    Lee, M.K.3
  • 73
    • 79959838081 scopus 로고    scopus 로고
    • Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma
    • Bell D, Berchuck A, Birrer M, et al. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
    • (2011) Nature , vol.474 , Issue.7353 , pp. 609-615
    • Bell, D.1    Berchuck, A.2    Birrer, M.3
  • 74
    • 57149093237 scopus 로고    scopus 로고
    • BRCAness” syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations
    • Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530-5536.
    • (2008) J Clin Oncol , vol.26 , Issue.34 , pp. 5530-5536
    • Tan, D.S.1    Rothermundt, C.2    Thomas, K.3
  • 75
    • 84893470371 scopus 로고    scopus 로고
    • Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas
    • Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-775.
    • (2014) Clin Cancer Res , vol.20 , Issue.3 , pp. 764-775
    • Pennington, K.P.1    Walsh, T.2    Harrell, M.I.3
  • 76
    • 84868221110 scopus 로고    scopus 로고
    • Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
    • Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588-5599.
    • (2012) Cancer Res , vol.72 , Issue.21 , pp. 5588-5599
    • Murai, J.1    Huang, S.Y.2    Das, B.B.3
  • 77
    • 67650471685 scopus 로고    scopus 로고
    • Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
    • Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
    • (2009) N Engl J Med , vol.361 , Issue.2 , pp. 123-134
    • Fong, P.C.1    Boss, D.S.2    Yap, T.A.3
  • 78
    • 77954032829 scopus 로고    scopus 로고
    • Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
    • Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-2519.
    • (2010) J Clin Oncol , vol.28 , Issue.15 , pp. 2512-2519
    • Fong, P.C.1    Yap, T.A.2    Boss, D.S.3
  • 79
    • 77955039099 scopus 로고    scopus 로고
    • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial
    • Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
    • (2010) Lancet , vol.376 , Issue.9737 , pp. 245-251
    • Audeh, M.W.1    Carmichael, J.2    Penson, R.T.3
  • 80
    • 80052389761 scopus 로고    scopus 로고
    • Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study
    • Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
    • (2011) Lancet Oncol , vol.12 , Issue.9 , pp. 852-861
    • Gelmon, K.A.1    Tischkowitz, M.2    Mackay, H.3
  • 81
    • 84863010984 scopus 로고    scopus 로고
    • Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
    • Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379.
    • (2012) J Clin Oncol , vol.30 , Issue.4 , pp. 372-379
    • Kaye, S.B.1    Lubinski, J.2    Matulonis, U.3
  • 82
    • 84859523588 scopus 로고    scopus 로고
    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
    • Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-1392.
    • (2012) N Engl J Med , vol.366 , Issue.15 , pp. 1382-1392
    • Ledermann, J.1    Harter, P.2    Gourley, C.3
  • 83
    • 84903547236 scopus 로고    scopus 로고
    • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    • Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-861.
    • (2014) Lancet Oncol , vol.15 , Issue.8 , pp. 852-861
    • Ledermann, J.1    Harter, P.2    Gourley, C.3
  • 84
    • 52449111109 scopus 로고    scopus 로고
    • Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
    • Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14(12):3916-3925.
    • (2008) Clin Cancer Res , vol.14 , Issue.12 , pp. 3916-3925
    • Evers, B.1    Drost, R.2    Schut, E.3
  • 85
    • 55949092708 scopus 로고    scopus 로고
    • High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
    • Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079-17084.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , Issue.44 , pp. 17079-17084
    • Rottenberg, S.1    Jaspers, J.E.2    Kersbergen, A.3
  • 86
    • 84859864115 scopus 로고    scopus 로고
    • A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
    • Rajan A, Carter CA, Kelly RJ, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res. 2012;18(8):2344-2351.
    • (2012) Clin Cancer Res , vol.18 , Issue.8 , pp. 2344-2351
    • Rajan, A.1    Carter, C.A.2    Kelly, R.J.3
  • 87
    • 79952281417 scopus 로고    scopus 로고
    • A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
    • Khan OA, Gore M, Lorigan P, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer. 2011;104(5):750-755.
    • (2011) Br J Cancer , vol.104 , Issue.5 , pp. 750-755
    • Khan, O.A.1    Gore, M.2    Lorigan, P.3
  • 88
    • 84866564290 scopus 로고    scopus 로고
    • Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: A phase I study
    • Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2012;30(4):1493-1500.
    • (2012) Invest New Drugs , vol.30 , Issue.4 , pp. 1493-1500
    • Samol, J.1    Ranson, M.2    Scott, E.3
  • 89
    • 84905187284 scopus 로고    scopus 로고
    • Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses
    • dju089
    • Lee JM, Hays JL, Annunziata CM, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106(6):dju089.
    • (2014) J Natl Cancer Inst , vol.106 , Issue.6
    • Lee, J.M.1    Hays, J.L.2    Annunziata, C.M.3
  • 90
    • 84922354749 scopus 로고    scopus 로고
    • A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer
    • June 3-7, Chicago, Illinois. Abstract 5028
    • Liu J, Fleming GF, Tolaney SM, et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. Presented at: 2011 ASCO Annual Meeting; June 3-7, 2014; Chicago, Illinois. Abstract 5028.
    • (2014) Presented At: 2011 ASCO Annual Meeting
    • Liu, J.1    Fleming, G.F.2    Tolaney, S.M.3
  • 91
    • 84880777712 scopus 로고    scopus 로고
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial
    • Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882-892.
    • (2013) Lancet Oncol , vol.14 , Issue.9 , pp. 882-892
    • Sandhu, S.K.1    Schelman, W.R.2    Wilding, G.3
  • 92
    • 84887431012 scopus 로고    scopus 로고
    • Mechanisms of resistance to therapies targeting BRCA-mutant cancers
    • Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19(11):1381-1388.
    • (2013) Nat Med , vol.19 , Issue.11 , pp. 1381-1388
    • Lord, C.J.1    Ashworth, A.2
  • 93
    • 84883179862 scopus 로고    scopus 로고
    • Targeting the ERBB family in cancer: Couples therapy
    • Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13(9):663-673.
    • (2013) Nat Rev Cancer , vol.13 , Issue.9 , pp. 663-673
    • Tebbutt, N.1    Pedersen, M.W.2    Johns, T.G.3
  • 94
    • 41949100690 scopus 로고    scopus 로고
    • Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer
    • Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785(2):232-265.
    • (2008) Biochim Biophys Acta , vol.1785 , Issue.2 , pp. 232-265
    • Lafky, J.M.1    Wilken, J.A.2    Baron, A.T.3    Maihle, N.J.4
  • 95
    • 39249085402 scopus 로고    scopus 로고
    • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
    • Secord AA, Blessing JA, Armstrong DK, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(3):493-499.
    • (2008) Gynecol Oncol , vol.108 , Issue.3 , pp. 493-499
    • Secord, A.A.1    Blessing, J.A.2    Armstrong, D.K.3
  • 96
    • 23044511620 scopus 로고    scopus 로고
    • Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study
    • Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11(15):5539-5548.
    • (2005) Clin Cancer Res , vol.11 , Issue.15 , pp. 5539-5548
    • Schilder, R.J.1    Sill, M.W.2    Chen, X.3
  • 97
    • 84897020192 scopus 로고    scopus 로고
    • Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
    • Vergote IB, Jimeno A, Joly F, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol. 2014;32(4):320-326.
    • (2014) J Clin Oncol , vol.32 , Issue.4 , pp. 320-326
    • Vergote, I.B.1    Jimeno, A.2    Joly, F.3
  • 98
    • 0037440042 scopus 로고    scopus 로고
    • Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    • Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283-290.
    • (2003) J Clin Oncol , vol.21 , Issue.2 , pp. 283-290
    • Bookman, M.A.1    Darcy, K.M.2    Clarke-Pearson, D.3    Boothby, R.A.4    Horowitz, I.R.5
  • 99
    • 67349095676 scopus 로고    scopus 로고
    • Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group Study
    • Farley J, Fuchiuji S, Darcy KM, et al. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol. 2009;113(3):341-347.
    • (2009) Gynecol Oncol , vol.113 , Issue.3 , pp. 341-347
    • Farley, J.1    Fuchiuji, S.2    Darcy, K.M.3
  • 100
    • 33749003463 scopus 로고    scopus 로고
    • Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
    • Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24(26):4324-4332.
    • (2006) J Clin Oncol , vol.24 , Issue.26 , pp. 4324-4332
    • Gordon, M.S.1    Matei, D.2    Aghajanian, C.3
  • 101
    • 84879188868 scopus 로고    scopus 로고
    • A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
    • Kaye SB, Poole CJ, Dańska-Bidzińska A, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol. 2013;24(1):145-152.
    • (2013) Ann Oncol , vol.24 , Issue.1 , pp. 145-152
    • Kaye, S.B.1    Poole, C.J.2    Dańska-Bidzińska, A.3
  • 102
    • 84902545311 scopus 로고    scopus 로고
    • High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer
    • Davies S, Holmes A, Lomo L, et al. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol. 2014;33(4):402-410.
    • (2014) Int J Gynecol Pathol , vol.33 , Issue.4 , pp. 402-410
    • Davies, S.1    Holmes, A.2    Lomo, L.3
  • 103
    • 33749034462 scopus 로고    scopus 로고
    • ErbB-3 predicts survival in ovarian cancer
    • Tanner B, Hasenclever D, Stern K, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24(26):4317-4323.
    • (2006) J Clin Oncol , vol.24 , Issue.26 , pp. 4317-4323
    • Tanner, B.1    Hasenclever, D.2    Stern, K.3
  • 104
    • 77950216941 scopus 로고    scopus 로고
    • An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
    • Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010;70(6):2485-2494.
    • (2010) Cancer Res , vol.70 , Issue.6 , pp. 2485-2494
    • Schoeberl, B.1    Faber, A.C.2    Li, D.3
  • 105
    • 77649314140 scopus 로고    scopus 로고
    • An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells
    • Sheng Q, Liu X, Fleming E, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010;17(3):298-310.
    • (2010) Cancer Cell , vol.17 , Issue.3 , pp. 298-310
    • Sheng, Q.1    Liu, X.2    Fleming, E.3
  • 106
    • 0035901090 scopus 로고    scopus 로고
    • Inflammation and cancer: Back to Virchow?
    • Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545.
    • (2001) Lancet , vol.357 , Issue.9255 , pp. 539-545
    • Balkwill, F.1    Mantovani, A.2
  • 107
    • 24944554981 scopus 로고    scopus 로고
    • Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer
    • Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol. 2005;23(25):5950-5959.
    • (2005) J Clin Oncol , vol.23 , Issue.25 , pp. 5950-5959
    • Madhusudan, S.1    Muthuramalingam, S.R.2    Braybrooke, J.P.3
  • 108
    • 46249120755 scopus 로고    scopus 로고
    • A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer
    • Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol. 2008;19(7):1340-1346.
    • (2008) Ann Oncol , vol.19 , Issue.7 , pp. 1340-1346
    • Brown, E.R.1    Charles, K.A.2    Hoare, S.A.3
  • 109
    • 80052855899 scopus 로고    scopus 로고
    • Interleukin-6 as a therapeutic target in human ovarian cancer
    • Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011 15;17(18):6083-6096.
    • (2011) Clin Cancer Res , vol.15-17 , Issue.18 , pp. 6083-6096
    • Coward, J.1    Kulbe, H.2    Chakravarty, P.3
  • 110
    • 84905753981 scopus 로고    scopus 로고
    • Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer
    • May 30-June 3, Chicago, Illinois. Abstract 5511
    • Hamanishi J, Mandai M, Ikeda T, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. Presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 5511.
    • (2014) Presented At: 2014 ASCO Annual Meeting
    • Hamanishi, J.1    Mandai, M.2    Ikeda, T.3
  • 111
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
    • (2012) N Engl J Med , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 112
    • 0023100453 scopus 로고
    • Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity
    • Miotti S, Canevari S, Ménard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987;39(3):297-303.
    • (1987) Int J Cancer , vol.39 , Issue.3 , pp. 297-303
    • Miotti, S.1    Canevari, S.2    Ménard, S.3
  • 113
    • 39249085399 scopus 로고    scopus 로고
    • Folate receptor alpha as a tumor target in epithelial ovarian cancer
    • Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619-626.
    • (2008) Gynecol Oncol , vol.108 , Issue.3 , pp. 619-626
    • Kalli, K.R.1    Oberg, A.L.2    Keeney, G.L.3
  • 114
    • 84862808121 scopus 로고    scopus 로고
    • Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
    • Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6(3):360-369.
    • (2012) Mol Oncol , vol.6 , Issue.3 , pp. 360-369
    • Chen, Y.L.1    Chang, M.C.2    Huang, C.Y.3
  • 115
    • 0031944910 scopus 로고    scopus 로고
    • Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer
    • Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998;79(2):121-126.
    • (1998) Int J Cancer , vol.79 , Issue.2 , pp. 121-126
    • Toffoli, G.1    Russo, A.2    Gallo, A.3
  • 116
    • 84877579319 scopus 로고    scopus 로고
    • Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
    • Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129(3):452-458.
    • (2013) Gynecol Oncol , vol.129 , Issue.3 , pp. 452-458
    • Armstrong, D.K.1    White, A.J.2    Weil, S.C.3    Phillips, M.4    Coleman, R.L.5
  • 117
    • 84922382553 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer
    • May 31-June 4, Chicago, Illinois. Abstract TPS255
    • Elit L, Konner J, Armstrong DK, et al. A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. Presented at: 2013 ASCO Annual Meeting; May 31-June 4, 2014; Chicago, Illinois. Abstract TPS255.
    • (2014) Presented At: 2013 ASCO Annual Meeting
    • Elit, L.1    Konner, J.2    Armstrong, D.K.3
  • 118
    • 79961137145 scopus 로고    scopus 로고
    • PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum resistant ovarian cancer
    • Abstract 5045
    • Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum resistant ovarian cancer. J Clin Oncol. 2011;29:343s. Abstract 5045.
    • (2011) J Clin Oncol , vol.29 , Issue.343
    • Naumann, R.W.1    Coleman, R.L.2    Burger, R.A.3
  • 119
    • 47349112424 scopus 로고    scopus 로고
    • Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways
    • Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem. 2008;114(1):17-22.
    • (2008) Arch Physiol Biochem , vol.114 , Issue.1 , pp. 17-22
    • Werner, H.1    Weinstein, D.2    Bentov, I.3
  • 120
    • 0036111682 scopus 로고    scopus 로고
    • Insulin-like growth factors and cancer
    • Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol. 2002;3(5):298-302.
    • (2002) Lancet Oncol , vol.3 , Issue.5 , pp. 298-302
    • Fürstenberger, G.1    Senn, H.J.2
  • 121
    • 84873884157 scopus 로고    scopus 로고
    • Targeting IGF-1 signaling pathways in gynecologic malignancies
    • Bruchim I, Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets. 2013;17(3):307-320.
    • (2013) Expert Opin Ther Targets , vol.17 , Issue.3 , pp. 307-320
    • Bruchim, I.1    Werner, H.2
  • 122
    • 77958067823 scopus 로고    scopus 로고
    • Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer
    • Buck E, Gokhale PC, Koujak S, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther. 2010;9(10):2652-2664.
    • (2010) Mol Cancer Ther , vol.9 , Issue.10 , pp. 2652-2664
    • Buck, E.1    Gokhale, P.C.2    Koujak, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.